These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30310468)

  • 61. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
    Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
    Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neuronal nitric oxide synthase and its interaction with soluble guanylate cyclase is a key factor for the vascular dysfunction of experimental sepsis.
    Nardi GM; Scheschowitsch K; Ammar D; de Oliveira SK; Arruda TB; Assreuy J
    Crit Care Med; 2014 Jun; 42(6):e391-400. PubMed ID: 24717470
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow.
    Rogers NM; Seeger F; Garcin ED; Roberts DD; Isenberg JS
    Front Physiol; 2014; 5():134. PubMed ID: 24772092
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction.
    Wang-Rosenke Y; Mika A; Khadzhynov D; Loof T; Neumayer HH; Peters H
    J Urol; 2011 Sep; 186(3):1142-9. PubMed ID: 21784461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
    Dumitrascu R; Weissmann N; Ghofrani HA; Dony E; Beuerlein K; Schmidt H; Stasch JP; Gnoth MJ; Seeger W; Grimminger F; Schermuly RT
    Circulation; 2006 Jan; 113(2):286-95. PubMed ID: 16391154
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy.
    McMahon TJ; Bryan NS
    Am J Cardiol; 2017 Oct; 120(8S):S89-S95. PubMed ID: 29025575
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
    Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
    Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].
    Sommer N; Richter MJ; Tello K; Grimminger F; Seeger W; Ghofrani HA; Gall H
    Internist (Berl); 2017 Sep; 58(9):937-957. PubMed ID: 28819824
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.
    Nagayama T; Zhang M; Hsu S; Takimoto E; Kass DA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):380-7. PubMed ID: 18456872
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets.
    Lázár Z; Mészáros M; Bikov A
    Curr Med Chem; 2020; 27(42):7168-7188. PubMed ID: 32442078
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
    Spreemann T; Bertram H; Happel CM; Kozlik-Feldmann R; Hansmann G
    Pulm Circ; 2018; 8(1):2045893217743123. PubMed ID: 29099661
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
    Yao A
    J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.
    Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L
    Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment.
    Kondo T; Okumura N; Adachi S; Murohara T
    Nagoya J Med Sci; 2019 Feb; 81(1):19-30. PubMed ID: 30962652
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
    Murata M; Kawakami T; Kataoka M; Kohno T; Itabashi Y; Fukuda K
    Pulm Circ; 2018; 8(1):2045893217746111. PubMed ID: 29251547
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs.
    Tzao C; Nickerson PA; Russell JA; Gugino SF; Steinhorn RH
    Pediatr Pulmonol; 2001 Feb; 31(2):97-105. PubMed ID: 11180684
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
    Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
    Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.